Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Island Pharmaceuticals Ltd (ILA) Share Price & Analysis

24 Followers

ILA Stock Chart & Stats

A$0.32-A$0.01(-1.54%)
At close: 4:00 PM GMT+11
AU$0.3AU$0.35AU$0.4AU$0.45Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.30 - AUD 0.32
52-Week Range
AUD 0.26 - AUD 0.63
Previous Close
AUD 0.33
Volume
N/A
Average Volume (3M)
225.31K
Market Cap
AUD 94.75M
Enterprise Value
AUD 99.58M
Total Cash (Recent Filing)
AUD 12.87M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
-0.66
Next Earnings
Mar 03, 2027 (Est.)
EPS Estimate
-0.02
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The absence of reported debt limits balance-sheet financial risk and avoids interest obligations that could further pressure a loss-making business. This gives Island Pharmaceuticals greater flexibility to allocate available capital toward research and development while reducing near-term refinancing exposure.

Growing Equity Base

The larger equity base provides a stronger capital foundation than the prior year and supports ongoing operations while the company advances its development programs. Although losses can erode this support over time, the reported increase improves financial resilience relative to FY2025.

Focused Antiviral Strategy

A clearly defined focus on antiviral and infectious disease therapies gives the business a consistent strategic direction. Concentrating development resources on this area may help management prioritize clinical and regulatory execution rather than dispersing effort across unrelated therapeutic categories.

Bears Say

Widening Losses

The sharp deterioration in operating and net results shows that the current business remains far from profitability. Persistently widening losses reduce retained capital, increase reliance on future funding, and make financial progress dependent on successful development and eventual commercialisation.

Persistent Cash Burn

Consistently negative operating and free cash flow means research and operations are not self-funded by the business. Continued cash consumption can reduce financial flexibility over the next several quarters and leave the company dependent on external capital to maintain its development activities.

Absent Revenue Base

The collapse to zero reported revenue and negative recent gross profit highlights the company’s pre-commercial position and lack of a dependable operating revenue stream. Until a candidate reaches commercialisation, funding requirements remain disconnected from customer receipts and normal business profitability.

Island Pharmaceuticals Ltd News

ILA FAQ

What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.26 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$94.75M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s next earnings report is estimated for Mar 03, 2027 (not yet confirmed), which is in 111 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Aug 26, 2026. The company reported -AU$0.017 earnings per share for the quarter, missing the consensus estimate of -AU$0.012 by -AU$0.005.
Is Island Pharmaceuticals Ltd overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.02.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 296,096,680 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.017 in its last earnings report, missing expectations of -AU$0.012. Following the earnings report the stock price went down -1.075%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology